<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077452</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0102</org_study_id>
    <nct_id>NCT02077452</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to determine the safety, tolerability, pharmacokinetics and
      pharmacodynamics of HMS5552 following multiple ascending doses in patients with type 2
      diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind and placebo-controlled study with multiple oral doses
      of HMS5552 given to patients with type 2 diabetes mellitus who never accepted anti-diabetic
      drug for treatment before.

      The primary objective is to characterize the safety and tolerability of HMS5552 following
      multiple ascending doses in patients with type 2 diabetes mellitus after BID dosing for 8
      days.

      The secondary objectives include:

        1. To determine the single dose and steady state pharmacokinetics of HMS5552 in patients
           with type 2 diabetes

        2. To evaluate the single dose and steady state pharmacodynamics of HMS5552 in patients
           with type 2 diabetes

        3. To further explore food-effect on HMS5552 pharmacokinetics and pharmacodynamics

      A maximum total of 80 patients (10 in each dose group and assuming a maximum of 5~8 dose
      levels). There will be 8 active and 2 placebo patients in each dose group. The safety,
      tolerability, pharmacokinetics and pharmacodynamics data after each dose cohort will be
      reviewed in blinded fashion before escalation to the next dose cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.</measure>
    <time_frame>up to 15 days after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The single dose and steady state pharmacokinetics (with food and fasting) of HMS5552 will be described by estimating parameters of AUCinf, AUC0-t, Cmax, Tmax, Ae, T1/2, CL/f, CLr/f, accumulation index and fluctuation index.</measure>
    <time_frame>up to day 8 post-dose</time_frame>
    <description>Single dose (Day 1) plasma and urine pharmacokinetic parameters (postprandial)
Single dose (Day 3) plasma and urine pharmacokinetic parameters (fasting)
Steady state (Day 7) plasma and urine pharmacokinetic parameters (postprandial)
Steady state (Day 8) plasma and urine pharmacokinetic parameters (fasting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single dose and steady state (fasting and postprandial) pharmacodynamic variables will include maximum absolute and percent change in plasma glucose level, AUC0-4, AUC0-16, AUC16-24, AUC0-24 hr of plasma glucose.</measure>
    <time_frame>up to 4 hour post-dose and up to 24 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)</measure>
    <time_frame>up to 6 hour post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 25~400mg. Oral administration, twice per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 25~400mg. Oral administration, twice per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 25~400mg. Oral administration, twice per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 25~400mg. Oral administration, once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 25~400mg. Oral administration, twice per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with type 2 diabetes

          -  Age: 18 to 65 years

          -  BMI: 20 to 29 kg/m2

          -  Mentally, physically and legally eligible to give informed consent.

          -  Willingness to adhere to the protocol requirement.

        Exclusion Criteria:

          -  Subjects with type 1 diabetes

          -  Episodes of hypoglycemia

          -  Unstable cardiovascular diseases

          -  Hepatic diseases

          -  Kidney disease

          -  Mental or central nervous system diseases

          -  Clinical abnormal findings in ECG, labs and physical exams
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong ZHU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucokinase activator</keyword>
  <keyword>Phase I</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

